Literature DB >> 10604863

Glutathione and N-acetylcysteine conjugates of alpha-methyldopamine produce serotonergic neurotoxicity: possible role in methylenedioxyamphetamine-mediated neurotoxicity.

F Bai1, S S Lau, T J Monks.   

Abstract

Direct injection of either 3,4-(+/-)-methylenedioxymethamphetamine (MDMA) or 3,4-(+/-)-methylenedioxyamphetamine (MDA) into the brain fails to reproduce the serotonergic neurotoxicity seen following peripheral administration. The serotonergic neurotoxicity of MDA and MDMA therefore appears to be dependent upon the generation of a neurotoxic metabolite, or metabolites, the identity of which remains unclear. alpha-Methyldopamine (alpha-MeDA) is a major metabolite of both MDA and MDMA. We have shown that intracerebroventricular (icv) injection of 2,5-bis(glutathion-S-yl)-alpha-methyldopamine [2, 5-bis(glutathion-S-yl)-alpha-MeDA] causes decreases in serotonin concentrations in the striatum, cortex, and hippocampus, and neurobehavioral effects similar to those seen following MDA and MDMA administration. In contrast, although 5-(glutathion-S-yl)-alpha-methyldopamine [5-(glutathion-S-yl)-alpha-MeDA] and 5-(N-acetylcystein-S-yl)-alpha-methyldopamine [5-(N-acetylcystein-S-yl)-alpha-MeDA] produce neurobehavioral changes similar to those seen with MDA and MDMA, and acute changes in brain 5-HT and dopamine concentrations, neither conjugate caused long-term decreases in 5-HT concentrations. We now report that direct intrastriatal or intracortical administration of 5-(glutathion-S-yl)-alpha-MeDA (4 x 200 or 4 x 400 nmol), 5-(N-acetylcystein-S-yl)-alpha-MeDA (4 x 7 or 4 x 20 nmol), and 2, 5-bis(glutathion-S-yl)-alpha-MeDA (4 x 150 or 4 x 300 nmol) causes significant decreases in striatal and cortical 5-HT concentrations (7 days following the last injection). Interestingly, intrastriatal injection of 5-(glutathion-S-yl)-alpha-MeDA or 2, 5-bis(glutathion-S-yl)-alpha-MeDA, but not 5-(N-acetylcystein-S-yl)-alpha-methyldopamine, also caused decreases in 5-HT concentrations in the ipsilateral cortex. The same pattern of changes was seen when the conjugates were injected into the cortex. The effects of the thioether conjugates of alpha-MeDA were confined to 5-HT nerve terminal fields, since no significant changes in monoamine neurotransmitter levels were detected in brain regions enriched with 5-HT cell bodies (midbrain/diencephalon/telencephalon and pons/medulla). In addition, the effects of the conjugates were selective with respect to the serotonergic system, as no significant changes were seen in dopamine or norepinephrine concentrations. The results indicate that thioether conjugates of alpha-MeDA are selective serotonergic neurotoxicants. Nonetheless, a role for these conjugates in the toxicity observed following systemic administration of MDA and MDMA remains to be demonstrated, and requires further experimentation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10604863     DOI: 10.1021/tx990084t

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  32 in total

1.  In vitro metabolism of 3,4-methylenedioxymethamphetamine in human hepatocytes.

Authors:  Corinne Ramaley; Susan C Leonard; Jeffrey D Miller; Denita Takesha-Mashia Wilson; Sai Y Chang; Qingyu Chen; Feng Li; Chengan Du
Journal:  J Anal Toxicol       Date:  2014-03-28       Impact factor: 3.367

2.  Serotonergic modulation of male-like pseudocopulatory behavior in the parthenogenetic whiptail lizard, Cnemidophorus uniparens.

Authors:  Brian George Dias; David Crews
Journal:  Horm Behav       Date:  2006-06-21       Impact factor: 3.587

3.  Regulation of pseudosexual behavior in the parthenogenetic whiptail lizard, Cnemidophorus uniparens.

Authors:  Brian George Dias; David Crews
Journal:  Endocrinology       Date:  2008-05-15       Impact factor: 4.736

4.  Stereoselective urinary MDMA (ecstasy) and metabolites excretion kinetics following controlled MDMA administration to humans.

Authors:  Andrea E Schwaninger; Markus R Meyer; Allan J Barnes; Erin A Kolbrich-Spargo; David A Gorelick; Robert S Goodwin; Marilyn A Huestis; Hans H Maurer
Journal:  Biochem Pharmacol       Date:  2011-09-29       Impact factor: 5.858

Review 5.  Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function.

Authors:  M Isabel Colado; Esther O'Shea; A Richard Green
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

6.  Structural identification of novel glucoside and glucuronide metabolites of (-)-epigallocatechin-3-gallate in mouse urine using liquid chromatography/electrospray ionization tandem mass spectrometry.

Authors:  Shengmin Sang; Chung S Yang
Journal:  Rapid Commun Mass Spectrom       Date:  2008-11       Impact factor: 2.419

7.  N-Acetylcysteine enhances the lung cancer inhibitory effect of epigallocatechin-3-gallate and forms a new adduct.

Authors:  Joshua D Lambert; Shengmin Sang; Chung S Yang
Journal:  Free Radic Biol Med       Date:  2007-12-23       Impact factor: 7.376

8.  Hydrolysis of 3,4-methylenedioxymethamphetamine (MDMA) metabolite conjugates in human, squirrel monkey, and rat plasma.

Authors:  Melanie Mueller; Erin A Kolbrich-Spargo; Frank T Peters; Marilyn A Huestis; George A Ricaurte; Hans H Maurer
Journal:  Anal Bioanal Chem       Date:  2009-01-30       Impact factor: 4.142

9.  Glial cell response to 3,4-(+/-)-methylenedioxymethamphetamine and its metabolites.

Authors:  Joseph M Herndon; Aram B Cholanians; Serrine S Lau; Terrence J Monks
Journal:  Toxicol Sci       Date:  2013-12-03       Impact factor: 4.849

10.  Further studies on the role of metabolites in (+/-)-3,4-methylenedioxymethamphetamine-induced serotonergic neurotoxicity.

Authors:  Melanie Mueller; Jie Yuan; Anne Felim; Anne Neudörffer; Frank T Peters; Hans H Maurer; Una D McCann; Martine Largeron; George A Ricaurte
Journal:  Drug Metab Dispos       Date:  2009-07-23       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.